Department of Psychology, Arizona State University, 950 S. McAllister Ave, PO Box 871104, Tempe, AZ 85287-1104, USA.
CNS Neurol Disord Drug Targets. 2013 Aug;12(5):619-32. doi: 10.2174/1871527311312050010.
Schizophrenia affects approximately 1% of the world population, and the majority of pharmacologically based treatments for this disorder are ligands that interact with monoaminergic transmission. However, there is a wealth of evidence that various neuropeptides are often co-released with monoamine neurotransmitters, and that ligands acting at neuropeptide receptors modulate monoaminergic transmission as well as schizophrenia-related behaviors in preclinical animal models. Such neuropeptide systems include neurotensin, cholecystokinin, corticotropin releasing factor, neuropeptide Y, oxytocin, opioid peptides, tachykinins, thyrotropin-releasing hormone, and orexins. The purpose of this review will be to summarize the existing preclinical and clinical literature on the role of various neuropeptide systems as modulators of schizophrenia-related behaviors, and the potential of targeting these systems for the development of novel antipsychotic medications.
精神分裂症影响着全球约 1%的人口，而大多数针对这种疾病的药物治疗都是基于与单胺能传递相互作用的配体。然而，有大量证据表明，各种神经肽通常与单胺神经递质一起被释放，并且作用于神经肽受体的配体也可以调节单胺能传递以及临床前动物模型中的与精神分裂症相关的行为。这样的神经肽系统包括神经降压素、胆囊收缩素、促肾上腺皮质激素释放因子、神经肽 Y、催产素、阿片肽、速激肽、促甲状腺素释放激素和食欲素。本文综述的目的将总结现有关于各种神经肽系统作为与精神分裂症相关行为调节剂的作用的临床前和临床文献，以及针对这些系统开发新型抗精神病药物的潜力。
